Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 6/2017

01-06-2017 | Review

Role of MiRNAs in Inflammatory Bowel Disease

Authors: Bo Cao, Xin Zhou, Jiaojiao Ma, Wei Zhou, Wanli Yang, Daiming Fan, Liu Hong

Published in: Digestive Diseases and Sciences | Issue 6/2017

Login to get access

Abstract

Inflammatory bowel diseases (IBD), mainly including Crohn’s disease and ulcerative colitis, are characterized by chronic inflammation of the gastrointestinal tract. Despite improvements in detection, drug treatment and surgery, the pathogenesis of IBD has not been clarified. A number of miRNAs have been found to be involved in the initiation, development and progression of IBD, and they may have the potential to be used as biomarkers and therapeutic targets. Here, we have summarized the recent advances about the roles of miRNAs in IBD and analyzed the contribution of miRNAs to general diagnosis, differential diagnosis and activity judgment of IBD. Furthermore, we have also elaborated the promising role of miRNAs in IBD-related cancer prevention and prognosis prediction.
Literature
1.
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.PubMedCrossRef
2.
3.
Gazouli M, Papaconstantinou I, Stamatis K, et al. Association study of genetic variants in miRNAs in patients with inflammatory bowel disease: preliminary results. Dig Dis Sci. 2013;58:2324–2328.PubMedCrossRef
4.
5.
6.
Da Sacco L, Masotti A. Recent insights and novel bioinformatics tools to understand the role of MicroRNAs binding to 5′ untranslated region. Int J Mol Sci. 2013;14:480–495.CrossRef
7.
Fang Z, Tang J, Bai Y, et al. Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J Exp Clin Cancer Res. 2015;34:86.PubMedPubMedCentralCrossRef
8.
Huang SP, Lévesque E, Guillemette C, et al. Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer. Int J Cancer. 2014;11:2661–2667.CrossRef
9.
Shen Y, Pan Y, Xu L, et al. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol. 2015;36:4525–4534.PubMedCrossRef
10.
Zhao HM, Wei W, Sun YH, Gao JH, Wang Q, Zheng JH. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells. Tumor Biol. 2015;36:6867–6873.CrossRef
11.
Honardoost MA, Naghavian R, Ahmadinejad F, Hosseini A, Ghaedi K. Integrative computational mRNA-miRNA interaction analyses of the autoimmune-deregulated miRNAs and well-known Th17 differentiation regulators: an attempt to discover new potential miRNAs involved in Th17 differentiation. Gene. 2015;572:153–162.PubMedCrossRef
12.
Zeng L, Cui J, Wu H, Lu Q. The emerging role of circulating microRNAs as biomarkers in autoimmune diseases. Autoimmunity. 2014;47:419–429.PubMedCrossRef
13.
Lee S, Lim S, Ham O, et al. ROS-mediated bidirectional regulation of miRNA results in distinct pathologic heart conditions. Biochem Biophys Res Commun. 2015;465:349–355.PubMedCrossRef
14.
Zhu J, Zhang Y, Zhang W, et al. MicroRNA-142-5p contributes to Hashimoto’s thyroiditis by targeting CLDN1. J Transl Med. 2016;1:166.CrossRef
15.
Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology. 2008;135:1624–1635.PubMedCrossRef
16.
Haines RJ, Beard RS, Eitner RA, Chen L, Wu MH. TNFα/IFNγ mediated intestinal epithelial barrier dysfunction is attenuated by microRNA-93 downregulation of PTK6 in mouse colonic epithelial cells. PLoS ONE. 2016;4:e0154351.CrossRef
17.
Blander JM. Death in the intestinal epithelium—basic biology and implications for inflammatory bowel disease. FEBS J. 2016;283:2720–2730.PubMedCrossRef
18.
Okamoto R, Watanabe M. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol. 2016;1:11–21.CrossRef
19.
Fischer A, Gluth M, Weege F, et al. Glucocorticoids regulate barrier function and claudin expression in intestinal epithelial cells via MKP-1. Am J Physiol Gastrointest Liver Physiol. 2014;306:G218–G228.PubMedCrossRef
20.
21.
Sohn JJ, Schetter AJ, Yfantis HG, et al. Macrophages, nitric oxide and microRNAs are associated with DNA damage response pathway and senescence in inflammatory bowel disease. PLoS ONE. 2012;9:e44156.CrossRef
22.
Li SQ, Feng L, Jiang WD, et al. Deficiency of dietary niacin impaired gill immunity and antioxidant capacity, and changes its tight junction proteins via regulating NF-kappaB, TOR, Nrf2 and MLCK signaling pathways in young grass carp (Ctenopharyngodon idella). Fish Shellfish Immunol. 2016;55:212–222.PubMedCrossRef
23.
Ouyang J, Zhang ZH, Zhou YX, et al. Up-regulation of tight-junction proteins by p38 mitogen-activated protein kinase/p53 inhibition leads to a reduction of injury to the intestinal mucosal barrier in severe acute pancreatitis. Pancreas. 2016;45:1136–1144.PubMedCrossRef
24.
Xu F, Ye YT, Cai CF, et al. Observation of the middle intestinal tight junction structure, cloning and studying tissue distribution of the four Claudin genes of the grass carp. Fish Physiol Biochem. 2014;6:1783–1792.CrossRef
25.
Ye D, Guo S, Al-Sadi R, Ma TY. MicroRNA regulation of intestinal epithelial tight junction permeability. Gastroenterology. 2011;4:1323–1333.CrossRef
26.
Zhi X, Tao J, Li Z, et al. MiR-874 promotes intestinal barrier dysfunction through targeting AQP3 following intestinal ischemic injury. FEBS Lett. 2014;588:757–763.PubMedCrossRef
27.
Wang H, Chao K, Ng SC, et al. Pro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease. Genome Biol. 2016;17:58.PubMedPubMedCentralCrossRef
28.
Yang Y, Ma Y, Shi C, Chen H, et al. Overexpression of miR-21 in patients with ulcerative colitis impairs intestinal epithelial barrier function through targeting the Rho GTPase RhoB. Biochem Biophys Res Commun. 2013;434:746–752.PubMedCrossRef
29.
Shi C, Liang Y, Yang J, et al. MicroRNA-21 knockout improve the survival rate in DSS induced fatal colitis through protecting against inflammation and tissue injury. PLoS ONE. 2013;8:e66814.PubMedPubMedCentralCrossRef
30.
Nijhuis A, Biancheri P, Lewis A, et al. In Crohn’s disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts. Clin Sci. 2014;127:341–350.PubMedCrossRef
31.
Chen Y, Ge W, Xu L, et al. miR-200b is involved in intestinal fibrosis of Crohn’s disease. Int J Mol Med. 2012;29:601–606.PubMedPubMedCentral
32.
Zidar N, Boštjančič E, Jerala M, et al. Down-regulation of microRNAs of the miR-200 family and up-regulation of Snail and Slug in inflammatory bowel diseases—hallmark of epithelial-mesenchymal transition. J Cell Mol Med. 2016;20:1813–1820.PubMedPubMedCentralCrossRef
33.
Paraskevi A, Theodoropoulos G, Papaconstantinou I, et al. Circulating MicroRNA in inflammatory bowel disease. J Crohns Colitis. 2012;6:900–904.PubMedCrossRef
34.
Min M, Peng L, Yang Y, Guo M, Wang W, Sun G. MicroRNA-155 Is Involved in the Pathogenesis of Ulcerative Colitis by Targeting FOXO3a. Inflamm Bowel Dis. 2014;20:652–659.PubMedCrossRef
35.
Pathak S, Grillo AR, Scarpa M, et al. MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis. Exp Mol Med. 2015;47:e164.PubMedPubMedCentralCrossRef
36.
Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology. 2008;135:1624.e24–1635.e24.
37.
Owaga E, Hsieh RH, Mugendi B, Masuku S, Shih CK, Chang JS. Th17 cells as potential probiotic therapeutic targets in inflammatory bowel diseases. Int J Mol Sci. 2015;16:20841–20858.PubMedPubMedCentralCrossRef
38.
Murphy EP, Crean D. Molecular interactions between NR4A orphan nuclear receptors and NF-kappaB are required for appropriate inflammatory responses and immune cell homeostasis. Biomolecules. 2015;5:1302–1318.PubMedPubMedCentralCrossRef
39.
Pedros C, Duguet F, Saoudi A, Chabod M. Disrupted regulatory T cell homeostasis in inflammatory bowel diseases. World J Gastroenterol. 2016;22:974–995.PubMedPubMedCentralCrossRef
40.
Chuang AY, Chuang JC, Zhai Z, Wu F, Kwon JH. NOD2 expression is regulated by microRNAs in colonic epithelial HCT116 cells. Inflamm Bowel Dis. 2014;20:126–135.PubMedPubMedCentralCrossRef
41.
Wu W, He C, Liu C, et al. miR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD. Gut. 2015;64:1755–1764.PubMedCrossRef
42.
Xue X, Feng T, Yao S, et al. Microbiota downregulates dendritic cell expression of miR-10a, which targets IL-12/IL-23p40. J Immunol. 2011;187:5879–5886.PubMedPubMedCentralCrossRef
43.
Ghorpade DS, Sinha AY, Holla S, Singh V, Balaji KN. NOD2-nitric oxide-responsive microRNA-146a activates sonic hedgehog signaling to orchestrate inflammatory responses in murine model of inflammatory bowel disease. J Biol Chem. 2013;288:33037–33048.PubMedPubMedCentralCrossRef
44.
Pierdomenico M, Cesi V, Cucchiara S, et al. NOD2 is regulated by mir-320 in physiological conditions but this control is altered in inflamed tissues of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:315–326.PubMedCrossRef
45.
Ayyadurai S, Charania MA, Xiao B, Viennois E, Zhang Y, Merlin D. Colonic miRNA expression/secretion, regulated by intestinal epithelial PepT1, plays an important role in cell-to-cell communication during colitis. PLoS ONE. 2014;2:e87614.CrossRef
46.
Xue X, Cao AT, Cao X, et al. Downregulation of microRNA-107 in intestinal CD11c(+) myeloid cells in response to microbiota and proinflammatory cytokines increases IL-23p19 expression. Eur J Immunol. 2014;44:673–682.PubMedPubMedCentralCrossRef
47.
Maharshak N, Shenhar-Tsarfaty S, Aroyo N, et al. MicroRNA-132 modulates cholinergic signaling and inflammation in human inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1346–1353.PubMedCrossRef
48.
Xu XM, Zhang HJ. MiRNAs as new molecular insights into inflammatory bowel disease: crucial regulators in autoimmunity and inflammation. World J Gastroenterol. 2016;22:2206–2218.PubMedPubMedCentral
49.
Wu F, Dong F, Arendovich N, Zhang J, Huang Y, Kwon JH. Divergent influence of microRNA-21 deletion on murine colitis phenotypes. Inflamm Bowel Dis. 2014;20:1972–1985.PubMedCrossRef
50.
Singh UP, Murphy AE, Enos RT, et al. miR-155 deficiency protects mice from experimental colitis by reducing T helper type 1type 17 responses. Immunology. 2014;3:478–489.CrossRef
51.
Kohlhaas S, Garden OA, Scudamore C, Turner M, Okkenhaug K, Vigorito E. Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol. 2009;182:2578–2582.PubMedCrossRef
52.
Chinen I, Nakahama T, Kimura A, et al. The aryl hydrocarbon receptor/microRNA-212/132 axis in T cells regulates IL-10 production to maintain intestinal homeostasis. Int Immunol. 2015;27:405–415.PubMedCrossRef
53.
Wang H, Flach H, Onizawa M, Wei L, McManus MT, Weiss A. Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nat Immunol. 2014;15:393–401.PubMedPubMedCentralCrossRef
54.
Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol. 2008;43:1–17.PubMedCrossRef
55.
Kaser A, Niederreiter L, Blumberg RS. Genetically determined epithelial dysfunction and its consequences for microflora-host interactions. Cell Mol Life Sci. 2011;68:3643–3649.PubMedPubMedCentralCrossRef
56.
57.
58.
Petkova DS, Viret C, Faure M. IRGM in autophagy and viral infections. Front Immunol. 2012;3:426.PubMed
59.
Brest P, Lapaquette P, Souidi M, et al. A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn’s disease. Nat Genet. 2011;43:242–245.PubMedCrossRef
60.
Plantinga TS, Crisan TO, Oosting M. Crohn’s disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut. 2011;9:1229–1235.CrossRef
61.
62.
63.
64.
Nguyen HT, Dalmasso G, Müller S, Carrière J, Seibold F, Darfeuille-Michaud A. Crohn’s disease-associated adherent invasive Escherichia coli modulate levels of microRNAs in intestinal epithelial cells to reduce autophagy. Gastroenterology. 2014;146:508–519.PubMedCrossRef
65.
Gibbings D, Mostowy S, Jay F, Schwab Y, Cossart P, Voinnet O. Selective autophagy degrades DICER and AGO2 and regulates miRNA activity. Nat Cell Biol. 2012;14:1314–1321.PubMedPubMedCentralCrossRef
66.
67.
Sibony M, Abdullah M, Greenfield L, et al. Microbial disruption of autophagy alters expression of the RISC component AGO2, a critical regulator of the miRNA silencing pathway. Inflamm Bowel Dis. 2015;21:2778–2786.PubMedPubMedCentralCrossRef
68.
Iwańczak B, Iwańczak F. Indicators of inflammatory process in stool in diagnostics and monitoring of inflammatory bowel diseases. Pol Merkur Lekarski. 2015;39:389–392.PubMed
69.
Vavricka SR, Rogler G, Gantenbein C, et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the swiss inflammatory bowel disease cohort. Inflamm Bowel Dis. 2015;8:1794–1800.CrossRef
70.
Vucelic B. Inflammatory bowel diseases: controversies in the use of diagnostic procedures. Dig Dis. 2009;27:269–277.PubMedCrossRef
71.
Sinh P, Shen B. Endoscopic evaluation of surgically altered bowel in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:1459–1471.PubMedPubMedCentral
72.
Canavese G, Villanacci V, Sapino A, et al. The diagnosis of inflammatory bowel disease is often unsupported in clinical practice. Dig Liver Dis. 2015;47:20–23.PubMedCrossRef
73.
Bor R, Balanyi Z, Farkas K, et al. Comparison of symptoms, laboratory parameters and illness perception in patients with irritable bowel syndrome and inflammatory bowel disease. Orv Hetil. 2015;156:933–938.PubMedCrossRef
74.
Guo Z, Wu R, Gong J, et al. Altered microRNA expression in inflamed and non-inflamed terminal ileal mucosa of adult patients with active Crohn’s disease. J Gastroenterol Hepatol. 2015;30:109–116.PubMedCrossRef
75.
76.
Jensen MD, Andersen RF, Christensen H, Nathan T, Kjeldsen J, Madsen JS. Circulating microRNAs as biomarkers of adult Crohn’s disease. Eur J Gastroenterol Hepatol. 2015;27:1038–1044.PubMedCrossRef
77.
Peck BC, Weiser M, Lee SE, et al. MicroRNAs classify different disease behavior phenotypes of Crohn’s disease and may have prognostic utility. Inflamm Bowel Dis. 2015;21:2178–2187.PubMedPubMedCentralCrossRef
78.
Lin J, Welker NC, Zhao Z, et al. Novel specific microRNA biomarkers in idiopathic inflammatory bowel disease unrelated to disease activity. Mod Pathol. 2014;27:602–608.PubMedCrossRef
79.
Duttagupta R, DiRienzo S, Jiang R, et al. Genome-wide maps of circulating miRNA biomarkers for ulcerative colitis. PLoS ONE. 2012;2:e31241.CrossRef
80.
Zahm AM, Thayu M, Hand NJ, Horner A, Leonard MB, Friedman JR. Circulating microRNA is a biomarker of pediatric crohn disease. J Pediatr Gastroenterol Nutr. 2011;53:26–33.PubMedCrossRef
81.
Brain O, Owens BM, Pichulik T, et al. The intracellular sensor NOD2 induces microRNA-29 expression in human dendritic cells to limit IL-23 release. Immunity. 2013;39:521–536.PubMedCrossRef
82.
Lewis A, Mehta S, Hanna LN, et al. Low serum levels of microRNA-19 are associated with a stricturing Crohn’s disease phenotype. Inflamm Bowel Dis. 2015;21:1926–1934.PubMedCrossRef
83.
Fasseu M, Tréton X, Guichard C, et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS ONE. 2010;10:e13160.CrossRef
84.
Zahm AM, Hand NJ, Tsoucas DM, Le Guen CL, Baldassano RN, Friedman JR. Rectal microRNAs are perturbed in pediatric inflammatory bowel disease of the colon. J Crohns Colitis. 2014;8:1108–1117.PubMedPubMedCentralCrossRef
85.
Wu F, Guo NJ, Tian H, et al. Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis. 2011;17:241–250.PubMedCrossRef
86.
Zhang C, Zhao Z, Osman H, Watson R, Nalbantoglu I, Lin J. Differential expression of miR-31 between inflammatory bowel disease and microscopic colitis. Microrna. 2014;3:155–159.PubMedCrossRef
87.
Matijašić M, Meštrović T, Perić M, et al. Modulating composition and metabolic activity of the gut microbiota in IBD patients. Int J Mol Sci. 2016;17:578.PubMedCentralCrossRef
88.
Coskun M, Bjerrum JT, Seidelin JB, Troelsen JT, Olsen J, Nielsen OH. miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis. World J Gastroenterol. 2013;19:4289–4299.PubMedPubMedCentralCrossRef
89.
Koukos G, Polytarchou C, Kaplan JL, et al. A microRNA signature in pediatric ulcerative colitis: deregulation of the miR-4284/CXCL5 pathway in the intestinal epithelium. Inflamm Bowel Dis. 2015;21:996–1005.PubMedPubMedCentralCrossRef
90.
Feng X, Wang H, Ye S, et al. Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IκBα. PLoS ONE. 2012;12:e52782.CrossRef
91.
Polytarchou C, Oikonomopoulos A, Mahurkar S, et al. Assessment of circulating microRNAs for the diagnosis and disease activity evaluation in patients with ulcerative colitis by using the nanostring technology. Inflamm Bowel Dis. 2015;21:2533–2539.PubMedCrossRef
92.
Krissansen GW, Yang Y, McQueen FM, et al. Overexpression of miR-595 and miR-1246 in the sera of patients with active forms of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:520–530.PubMedCrossRef
93.
Rogler G. Where are we heading to in pharmacological IBD therapy? Pharmacol Res. 2015;100:220–227.PubMedCrossRef
94.
95.
Chen Y, Wang C, Liu Y, et al. miR-122 targets NOD2 to decrease intestinal epithelial cell injury in Crohn’s disease. Biochem Biophys Res Commun. 2013;438:133–139.PubMedCrossRef
96.
Huang Z, Shi T, Zhou Q, et al. miR-141 Regulates colonic leukocytic trafficking by targeting CXCL12β during murine colitis and human Crohn’s disease. Gut. 2014;63:1247–1257.PubMedCrossRef
97.
Huang Z, Shi T, Zhou Q, et al. MicroRNA-146b improves intestinal injury in mouse colitis by activating nuclear factor-kappaB and improving epithelial barrier function. J Gene Med. 2013;15:249–260.
98.
Zwiers A, Kraal L, Van de Pouw Kraan T, Wurdinger T, Bouma G, Kraal G. Cutting edge: a variant of the IL-23r gene associated with inflammatory bowel disease induces loss of microRNA regulation and enhanced protein production. J Immunol. 2012;4:1573–1577.CrossRef
99.
Van der Goten J, Vanhove W, Lemaire K, et al. Integrated miRNA and mRNA expression profiling in inflamed colon of patients with ulcerative colitis. PLoS ONE. 2014;12:e116117.CrossRef
100.
El-Gowelli HM, Saad EI, Abdel-Galil AG, Ibrahim ER. Co-administration of α-lipoic acid and cyclosporine aggravates colon ulceration of acetic acid-induced ulcerative colitis via facilitation of NO/COX-2/miR-210 cascade. Toxicol Appl Pharmacol. 2015;288:300–312.PubMedCrossRef
101.
Ludwig K, Fassan M, Mescoli C, et al. PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis. Virchows Arch. 2013;462:57–63.PubMedCrossRef
102.
103.
Sohn JJ, Schetter AJ, Yfantis HG, et al. Macrophages, nitric oxide and microRNAs are associated with DNA damage response pathway and senescence in inflammatory bowel disease. PLoS ONE. 2012;7:e44156.PubMedPubMedCentralCrossRef
104.
Chen Y, Xiao Y, Ge W, et al. miR-200b inhibits TGF-b1-induced epithelial-mesenchymal transition and promotes growth of intestinal epithelial cells. Cell Death Dis. 2013;4:e541.PubMedPubMedCentralCrossRef
105.
Olaru AV, Yamanaka S, Vazquez C, et al. MicroRNA-224 negatively regulates p21 expression during late neoplastic progression in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:471–480.PubMedPubMedCentralCrossRef
106.
Necela BM, Carr JM, Asmann YW, Thompson EA. Differential Expression of microRNAs in tumors from chronically inflamed or genetic (APC Min/+) models of colon cancer. PLoS ONE. 2011;6:1–12.CrossRef
107.
108.
Goel A. MicroRNAs as therapeutic targets in colitis and colitis-associated cancer: tiny players with a giant impact. Gastroenterology. 2015;149:859–861.PubMedPubMedCentralCrossRef
109.
Polytarchou C, Hommes DW, Palumbo T, et al. MicroRNA214 is associated with progression of ulcerative colitis, and inhibition reduces development of colitis and colitis-associated cancer in mice. Gastroenterology. 2015;149:981–992.PubMedPubMedCentralCrossRef
110.
Olaru AV, Selaru FM, Mori Y, et al. Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation. Inflamm Bowel Dis. 2011;17:221–231.PubMedPubMedCentralCrossRef
111.
Kanaan Z, Rai SN, Eichenberger MR, et al. Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum Mutat. 2012;33:551–560.PubMedPubMedCentralCrossRef
112.
Chen G, Cao S, Liu F, Liu Y. miR-195 plays a role in steroid resistance of ulcerative colitis by targeting Smad7. Biochem J. 2015;471:357–367.PubMedCrossRef
113.
Fujioka S, Nakamichi I, Esaki M, Asano K, Matsumoto T, Kitazono T. Serum microRNA levels in patients with Crohn’s disease during induction therapy by infliximab. J Gastroenterol Hepatol. 2014;6:1207–1214.CrossRef
114.
Collins PD. Strategies for detecting colon cancer and dysplasia in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:860–863.PubMedCrossRef
115.
Benderska N, Dittrich AL, Knaup S, et al. miRNA-26b overexpression in ulcerative colitis-associated carcinogenesis. Inflamm Bowel Dis. 2015;21:2039–2051.PubMedPubMedCentralCrossRef
116.
Bai J, Li Y, Shao T, et al. Integrating analysis reveals microRNA-mediated pathway crosstalk among Crohn’s disease, ulcerative colitis and colorectal cancer. Mol Biosyst. 2014;9:2317–2328.CrossRef
117.
Ueda Y, Ando T, Nanjo S, Ushijima T, Sugiyama T. DNA methylation of microRNA-124a is a potential risk marker of colitis-associated cancer in patients with ulcerative colitis. Dig Dis Sci. 2014;59:2444–2451.PubMedCrossRef
118.
Wan J, Xia L, Xu W, Lu N. Expression and function of miR-155 in diseases of the gastrointestinal tract. Int J Mol Sci. 2016;17:709.PubMedCentralCrossRef
119.
Svrcek M, El-Murr N, Wanherdrick K, et al. Overexpression of microRNAs-155 and 21 targeting mismatch repair proteins in inflammatory bowel diseases. Carcinogenesis. 2013;34:828–834.PubMedCrossRef
120.
Tan YG, Zhang YF, Guo CJ, Yang M, Chen MY. Screening of differentially expressed microRNA in ulcerative colitis related colorectal cancer. Asian Pac J Trop Med. 2013;6:972–976.PubMedCrossRef
121.
Takagi T, Naito Y, Mizushima K, et al. Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis. J Gastroenterol Hepatol. 2010;25:129–133.CrossRef
Metadata
Title
Role of MiRNAs in Inflammatory Bowel Disease
Authors
Bo Cao
Xin Zhou
Jiaojiao Ma
Wei Zhou
Wanli Yang
Daiming Fan
Liu Hong
Publication date
01-06-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4567-1

Other articles of this Issue 6/2017

Digestive Diseases and Sciences 6/2017 Go to the issue

Original Article

Impact of an Endoscopic Quality Improvement Program Focused on Adenoma Detection on Sessile Serrated Adenoma/Polyp Detection

Original Article

Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure

Original Article

Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies

Original Article

Serum Cyclophilin A Correlates with Increased Tissue MMP-9 in Patients with Ulcerative Colitis, but Not with Crohn’s Disease

Original Article

Autophagy Genes of Host Responds to Disruption of Gut Microbial Community by Antibiotics

Review

Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits